Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment
Rui Han1,2,3,4, Yuqian Wang1,2, Lingeng Lu4,5,6
1Department of Chinese Medicine Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China.
Abstract:
This study builds upon the groundbreaking mRNA vaccine Nobel Prize win in 2023 for COVID-19 prevention, paving the way for next-generation mRNA cancer vaccines to revolutionize immunotherapy. Despite the existing challenges, such as the presence of a suppressive tumor microenvironment and the identification of cancer-associated antigens, recent results from the KEYNOTE-942 trial have successfully demonstrated the effectiveness of mRNA-based cancer treatments, providing clinical evidence for the first time. This trial aimed to evaluate the efficacy and safety of combining immune checkpoint inhibitors with mRNA-based therapies in treating cancer. This advancement undeniably represents new hope for hepatocellular carcinoma (HCC) patients. However, progress in this field remains limited. In this article, we summarized the current state of applying immune checkpoint inhibitors (ICIs) combined with neoantigen mRNA vaccines. Additionally, we discussed potential targets for designing novel mRNA vaccines and potential mRNA vaccine delivery vehicles. The objective of this article is to inspire enthusiasm for the exploration of innovative therapeutic strategies that combine ICIs with neoantigen mRNA vaccines for HCC treatment and HCC prevention.
Insights
Next-generation messenger RNA (mRNA) cancer vaccines show promise for immunotherapy, building on COVID-19 vaccine success. Combining mRNA therapies with immune checkpoint inhibitors offers new hope for treating and preventing hepatocellular carcinoma.
Area of Science:
- Oncology
- Immunotherapy
- Vaccine Development
Background:
- The 2023 Nobel Prize for mRNA COVID-19 vaccines highlights the potential of this technology.
- Challenges in cancer immunotherapy include the suppressive tumor microenvironment and identifying effective cancer antigens.
- The KEYNOTE-942 trial provides the first clinical evidence for mRNA-based cancer treatments.
Purpose of the Study:
- To review the current application of immune checkpoint inhibitors (ICIs) combined with neoantigen mRNA vaccines.
- To discuss potential targets for novel mRNA vaccine design.
- To explore potential mRNA vaccine delivery vehicles for cancer treatment.
Main Methods:
- Literature review of current research on ICIs and mRNA cancer vaccines.
- Analysis of findings from the KEYNOTE-942 trial.
- Discussion of challenges and future directions in mRNA cancer vaccine development.
Main Results:
- The KEYNOTE-942 trial demonstrated the efficacy and safety of combining ICIs with mRNA-based therapies.
- This combination therapy shows promise for hepatocellular carcinoma (HCC) treatment.
- Clinical evidence supports mRNA-based cancer treatments, offering new hope for patients.
Conclusions:
- Combining ICIs with neoantigen mRNA vaccines represents a significant advancement in cancer immunotherapy.
- Further exploration of novel mRNA vaccine targets and delivery systems is warranted.
- This therapeutic strategy holds potential for both HCC treatment and prevention.
